Progenics Collaborates with Veterans Affairs on AI Research Program for Medical Image Analysis

A close collaboration between the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS) and Progenics Pharmaceuticals will focus on the development and validation of artificial intelligence (AI) algorithms in medical images for disease management for veterans with prostate cancer. “The promise of AI in healthcare, specifically in this collaboration, is to increase the quality of care while driving down costs,” said Aseem Anand, PhD, vice president and site manager of EXINI Diagnostics, in an interview with MD+DI. EXINI Diagnostics, recently acquired by Progenics, specializes in medical imaging AI and the development of validated imaging biomarkers and medical devices. Its main focus is to support Progenics’ pipeline of prostate-specific membrane antigen (PSMA)–imaging radiopharmaceuticals, Anand said. In the initial phases of the collaboration, the VAGLAHS network will gain access to Progenics’s machine-learning platforms—the automated Bone Scan Index (aBSI) technology and PSMA platform. The FDA-cleared aBSI technology gives a fully quantitative assessment of bone scans that incorporates inferred masses of all lesions. Anand explained that in a prospectively defined, multi-institutional, phase-three study with 721 metastatic prostate cancer patients, aBSI was found to be an independent prognostic determinant of overall survival. The s...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news

Related Links:

We have successfully synthesized [18F]FABAAB, the first fluorine ‐18 labeled derivative of compound V‐9302 with an overall nondecay corrected yield of 3.66 ± 1.90%. in vitro experiments show Ki values of 90 and 125 µM for the PC‐3 and F98 cells, respectively. The experiments in the PC‐3 xenograft demonstrate a low uptake in the tumor tissue. The metabolic alterations in tumors make it possible to visualize the latter by means of positron emission tomography, enabling diagnosis and providing metabolic information. The alanine serine cysteine transporter ‐2 (ASCT‐2) is the main transporter of glutami...
Source: Journal of Labelled Compounds and Radiopharmaceuticals - Category: Biochemistry Authors: Tags: RESEARCH ARTICLE Source Type: research
Conclusions: Adding SRT to RP does not seem to result in other than acceptable side-effects in the majority of men receiving SRT when taking a long follow-up time (median 10 years after surgery) into account. However, a subset of men develop severe side-effects where rectal bleeding dominates. PMID: 32619133 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Publication date: Available online 2 July 2020Source: European UrologyAuthor(s): Philip Cornford, Jeremy Grummet, Stefano Fanti, on behalf of the EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel
Source: European Urology - Category: Urology & Nephrology Source Type: research
A prospective study of a urine and plasma biomarker test for the prediction of gleason ≥3 + 4 prostate cancer in a mixed cohort. Scand J Urol. 2020 Jul 01;:1-5 Authors: Poulsen MH, Feddersen S, Albitar M, Poulsen CA, Lund M, Pedersen TB, Mortensen MA, Lund L Abstract Purpose: Definitive diagnosis of prostate cancer is based on biopsies, a procedure associated with side-effects. The use of biomarkers in blood and urine could potentially help clinicians select patients for whom biopsies are needed. The aim of the study was to test a new urine and plasma biomarker test in detecting medium...
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Conclusion: The high accumulation of activity in the tumor and fast clearance from background organs was a common favorable characteristic of PSMA radioligands modified with ibuprofen as albumin-binding entity. 177Lu-Ibu-DAB-PSMA emerged as the most promising candidate; hence, more detailed preclinical investigations with this radioligand are warranted in view of a clinical translation.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: Our findings provide a first proof of concept to exploit CD98hc for non-invasive biomedical imaging. The novel Anticalin-based αhCD98hc radiopharmaceutical constitutes a promising tool for preclinical and, potentially, clinical applications in oncology.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: PERCIST 1.0 may provide significant prognostic information for patients with mCRPC undergoing systemic chemotherapy, particularly when incorporated with PSA treatment response criteria.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Prostate-specific membrane antigen (PSMA) targeted PET has a high detection rate for biochemical recurrence (BCR) of prostate cancer (PCa). Nevertheless, even at high prostate-specific antigen (PSA) levels (> 3 ng/ml), a relevant number of PSMA-PET scans are negative, mainly due to PSMA-negative PCa. Our objective was to investigate whether PSMA-expression patterns of the primary tumour on immunohistochemistry (IHC) are associated with PSMA-PET detection rate of recurrent PCa.Methods: Retrospective institutional review board approved single-centre analysis of patients who had undergone 68Ga-PSMA-11-PET for BCR after rad...
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-specific membrane antigen (PSMA) in vivo, which is the target molecule of 177Lu-PSMA-617 (Lu-PSMA) therapy. However, the correlation of PSMA expression and overall survival (OS) in patients treated with Lu-PSMA therapy is currently unclear; especially with regard to coexistence of high and low PSMA expressing metastases. To this end, this retrospective single arm study elucidates the correlation of PSMA expression and overall survival in patients treated with Lu-PSMA therapy. Additionally, PET based criteria to define low PSMA expression were explore...
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion68Ga-PSMA-PET/CT-based MDT is an efficient and safe treatment for oligometastatic PC patients. Proper patient selection might improve treatment outcomes.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Learning | Medical Devices | Nuclear Medicine | PET Scan | Prostate Cancer | Statistics | Study | Universities & Medical Training